Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Trine Heide Øllegaard"'
Publikováno v:
Case Reports in Dermatology, Vol 10, Iss 2, Pp 154-157 (2018)
Checkpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates of disseminated malignant melan
Externí odkaz:
https://doaj.org/article/2e3937843d554eb28d2cfffb866905b6
Autor:
Jesper Geert Pedersen, Mateo Sokac, Boe Sandahl Sørensen, Adam Andrzej Luczak, Ninna Aggerholm-Pedersen, Nicolai Juul Birkbak, Trine Heide Øllegaard, Martin Roelsgaard Jakobsen
Publikováno v:
Cancers; Volume 14; Issue 14; Pages: 3342
Pedersen, J G, Sokac, M, Sørensen, B S, Luczak, A A, Aggerholm-Pedersen, N, Birkbak, N J, Øllegaard, T H & Jakobsen, M R 2022, ' Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma ', Cancers, vol. 14, no. 14, 3342 . https://doi.org/10.3390/cancers14143342
Pedersen, J G, Sokac, M, Sørensen, B S, Luczak, A A, Aggerholm-Pedersen, N, Birkbak, N J, Øllegaard, T H & Jakobsen, M R 2022, ' Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma ', Cancers, vol. 14, no. 14, 3342 . https://doi.org/10.3390/cancers14143342
Background: Checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, yielding long-term survival in a considerable proportion of the patients. Yet, 40–60% of patients do not achieve a long-term benefit from such therapy, emph
Autor:
Martin R. Jakobsen, Trine Heide Øllegaard, Jesper Pedersen, Mateo Sokac, Nicolai Juul Birkbak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCheckpoint inhibitors have significantly improved treatment of metastatic melanoma. Yet, 40–60% of the patients do not achieve a long-term benefit from such immunotherapy. Thus, there is an urgent need to identify biomarkers that can pred
Autor:
Line Thing, Simonsen, Anne Mette Sjørslev, Schmidt, Trine Heide, Øllegaard, Inge Marie, Svane, Lars, Bastholt, Adam Andrzej, Luczak, Henrik, Schmidt
Publikováno v:
Ugeskrift for laeger. 181(24)
Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies in
Autor:
Line Thing Simonsen, Anne Mette Sjørslev Schmidt, Trine Heide Øllegaard, Inge Marie Svane, Lars Bastholt, Adam Andrzej Luczak, Henrik Schmidt
Publikováno v:
Simonsen, L T, Schmidt, A M S, Øllegaard, T H, Svane, I M, Bastholt, L, Luczak, A A & Schmidt, H 2019, ' Immunterapi til patienter med malignt melanom og hjernemetastaser ', Ugeskrift for Laeger, bind 181, V01190057 . < https://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser >
Simonsen, L T, Schmidt, A M S, Øllegaard, T H, Svane, I M, Bastholt, L, Luczak, A A & Schmidt, H 2019, ' Immunterapi til patienter med malignt melanom og hjernemetastaser ', Ugeskrift for Læger, bind 181, nr. 24, V01190057 . < https://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser >
Simonsen, L T, Schmidt, A M S, Øllegaard, T H, Svane, I M, Bastholt, L, Luczak, A A & Schmidt, H 2020, ' Immunterapi til patienter med malignt melanom og hjernemetastaser ', Ugeskrift for Laeger, bind 182, nr. 7, V01190057 . < http://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser >
University of Copenhagen
University of Southern Denmark
Simonsen, L T, Schmidt, A M S, Øllegaard, T H, Svane, I M, Bastholt, L, Luczak, A A & Schmidt, H 2019, ' Immunterapi til patienter med malignt melanom og hjernemetastaser ', Ugeskrift for Læger, bind 181, nr. 24, V01190057 . < https://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser >
Simonsen, L T, Schmidt, A M S, Øllegaard, T H, Svane, I M, Bastholt, L, Luczak, A A & Schmidt, H 2020, ' Immunterapi til patienter med malignt melanom og hjernemetastaser ', Ugeskrift for Laeger, bind 182, nr. 7, V01190057 . < http://ugeskriftet.dk/videnskab/immunterapi-til-patienter-med-malignt-melanom-og-hjernemetastaser >
University of Copenhagen
University of Southern Denmark
Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e1f7703e3f34cbb76639760545581969
https://vbn.aau.dk/da/publications/8c0d651b-c537-416b-85ad-402fd5f4b709
https://vbn.aau.dk/da/publications/8c0d651b-c537-416b-85ad-402fd5f4b709
Autor:
Lars Bastholt, Marco Donia, Trine Heide Øllegaard, Eva Ellebaek, Jens Bull Aaby, Henrik Schmidt, Inge Marie Svane, Lone Duval, Ulrich Heide Køhler, Lise Hoejberg
Publikováno v:
Donia, M, Ellebaek, E, Øllegaard, T H, Duval, L, Aaby, J B, Hoejberg, L, Køhler, U H, Schmidt, H, Bastholt, L & Svane, I M 2019, ' The real-world impact of modern treatments on the survival of patients with metastatic melanoma ', European Journal of Cancer, vol. 108, pp. 25-32 . https://doi.org/10.1016/j.ejca.2018.12.002
Donia, M, Ellebaek, E, Ollegaard, T H, Duval, L, Aaby, J B, Hojberg, L, Kohler, U H, Schmidt, H, Bastholt, L & Svane, I-M 2018, ' The real-world impact of modern treatments on the survival of patients with metastatic melanoma ', Annals of Oncology, vol. 29, no. Suppl. 8, pp. viii456 . https://doi.org/10.1093/annonc/mdy289.035
Donia, M, Ellebaek, E, Ollegaard, T H, Duval, L, Aaby, J B, Hojberg, L, Kohler, U H, Schmidt, H, Bastholt, L & Svane, I-M 2018, ' The real-world impact of modern treatments on the survival of patients with metastatic melanoma ', Annals of Oncology, vol. 29, no. Suppl. 8, pp. viii456 . https://doi.org/10.1093/annonc/mdy289.035
Between 2010 and 2015, pivotal trials with strict enrolment criteria led to the approval of several new treatments for metastatic melanoma (MM). We sought to determine the impact of these treatments in the 'real world'. We took advantage of the Danis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e5babd7c6cf169a064954c7f4bfc143
https://portal.findresearcher.sdu.dk/da/publications/190e869f-69b4-458c-a6fc-30760635d73b
https://portal.findresearcher.sdu.dk/da/publications/190e869f-69b4-458c-a6fc-30760635d73b
Autor:
Jeanette Bæhr Georgsen, Torben Steiniche, Nina Dabrosin, Karen Sloth Juul, Henrik Schmidt, Simon Andrup, Louise Bønnelykke Behrndtz, Trine Heide Øllegaard
Publikováno v:
Dabrosin, N, Sloth Juul, K, Bæhr Georgsen, J, Andrup, S, Schmidt, H, Steiniche, T, Heide Øllegaard, T & Bønnelykke Behrndtz, L 2019, ' Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status ', Melanoma Research, vol. 29, no. 1, pp. 30-37 . https://doi.org/10.1097/CMR.0000000000000515
Little is known about the infiltrative pattern of innate immune cells in primary melanoma compared with their paired metastases and in BRAF-mutated tumors. Therefore, our aim was to characterize the inflammatory microenvironment in primary ulcerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987b24d6813e9a79a9a3d83e1c3576c7
https://pure.au.dk/portal/da/publications/innate-immune-cell-infiltration-in-melanoma-metastases-affects-survival-and-is-associated-with-brafv600e-mutation-status(ff34db77-fabe-4ea1-b197-18309530c40e).html
https://pure.au.dk/portal/da/publications/innate-immune-cell-infiltration-in-melanoma-metastases-affects-survival-and-is-associated-with-brafv600e-mutation-status(ff34db77-fabe-4ea1-b197-18309530c40e).html
Autor:
Martin R. Jakobsen, Anne Tranberg Madsen, Trine Heide Øllegaard, Boe Sandahl Sorensen, Jesper Geert Pedersen, Ninna Aggerholm-Pedersen, Kristine Raaby Gammelgaard
Publikováno v:
Cancers
Cancers, Vol 12, Iss 1414, p 1414 (2020)
Pedersen, J G, Madsen, A T, Gammelgaard, K R, Aggerholm-Pedersen, N, Sørensen, B S, Øllegaard, T H & Jakobsen, M R 2020, ' Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors ', Cancers, vol. 12, no. 6, 1414 . https://doi.org/10.3390/cancers12061414
Volume 12
Issue 6
Cancers, Vol 12, Iss 1414, p 1414 (2020)
Pedersen, J G, Madsen, A T, Gammelgaard, K R, Aggerholm-Pedersen, N, Sørensen, B S, Øllegaard, T H & Jakobsen, M R 2020, ' Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors ', Cancers, vol. 12, no. 6, 1414 . https://doi.org/10.3390/cancers12061414
Volume 12
Issue 6
Purpose: Checkpoint inhibitors have significantly improved treatment of metastatic melanoma. However, 40&ndash
60% of patients do not respond to therapy, emphasizing the need for better predictive biomarkers for treatment response to immune chec
60% of patients do not respond to therapy, emphasizing the need for better predictive biomarkers for treatment response to immune chec